Bayer: Glimmer of hope from a possible landmark ruling in the USA

Bayer is at a critical juncture between operational recovery and structural legacy issues. While the pharmaceutical segment is generating reliable cash flows again with strong products like Nubeqa and a solid pipeline, the agricultural division remains heavily dependent on the global price cycle and regulatory interventions. The overall picture continues to be overshadowed by the legal risks associated with glyphosate, which tie up capital and also cost strategic flexibility. At the same time, the company is working on debt reduction and efficiency...